RE:RE:RE:RE:ZenithJK,
Resverlogix was originally re-organized into two companies back in 2013 so that Resverlogix would retain its R&D and compounds releated to indications involving a therapeutic increase in Apolipoprotein A-1, and all other R&D activities related to its epigenetic platform technology would be spun-off into what is now known as Zenith Epigenetics Ltd. (ZEL). This epigenetic platform spin off also included including compounds that at the time that did not modulate Apolipoprotein A-1. ZEL is a wholly-owned subsidiary of Zenith Capital Corp (ZCC).
It gets a little more complex because the Resverlogix Royalty Preferred Shares (RPSs) are owned by ZCC and not ZEL. There was also a
Zenith re-organization back in 2016. Theoretically, ZEL can be bought out separate from ZCC, allowing shareholders of ZCC to retain rights to the RPSs. Initially, the RPSs were just for a royalty/dividend for a percentage of revenue, if any, received by Resverlogix, it affiliates or any licensee, for compounds that result in a therapeutic relevant elevation in the plasma levels of ApoA-1. However, this was changed in the past few couple of years, if my memory serves me well, to include ALL Resverlogix compounds not just ones that modulate ApoA-1. So those RPSs can be pretty darn valuable if this all works out.
Regarding Zenith abandoning ZEN-3365.....I dug this up from a
prior post:
"
Similar argument for pursuing ZEN-3694 and ZEN-3717 instead of ZEN-3365. While there may or may not have been patent problems with pursuing ZEN-3365, they decided to avoid this and go ahead and pursue a supposedly superior molecule from the 3600- and 3700- series and avoid potential patent problems (or at the very least delays) with using the earlier 3300-series ZEN-3365.
From Masila's notes from the January 2016 Zenith AGM: "The challenges with that in Oct 2014 were based around intellectual property. We had moved forward very fast with that, but prior to our publishing of our IP, another company had published a document that didn’t completely cover/block us, but would have made it difficult legally. We went back to the drawing board and, after bragging about our massive platform and extensive IP, we went back to that and developed two very good lead programs going forward – ZEN 3694 and ZEN 3717. There were actually about 7 or 8 that we had to choose from, all superior to our first one. We’ve very happy about having that depth."
BDAZ